Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?

Marina Gorelik, Mahmoud Ahmad, David Grossman, Martin Grossman, Avram M. Cooperman

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Asymptomatic non-functioning pancreatic neuroendocrine tumors are indolent, slow-growing tumors, and surveillance is safe and reasonable. Despite consensus, size may be less important than grade and Ki-67 when making decisions regarding optimal therapy. Plans to proceed with surveillance or surgical resection require a multidisciplinary approach and a shared decision making process with colleagues, patients, and families. Decisions should be based on tumor characteristics, patient morbidities, preferences, and risks. As molecular diagnostics evolve, preoperative acquisition of tissue samples may become even more critical in choosing between operative management and surveillance.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalSurgical Clinics of North America
Issue number1
StatePublished - Feb 2018
Externally publishedYes


  • Nonfunctioning pancreatic neuroendocrine tumor (NF-PNET)
  • Pancreatic neuroendocrine tumor (PNET)
  • Surveillance


Dive into the research topics of 'Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors: Who, When, and How to Treat?'. Together they form a unique fingerprint.

Cite this